Bringing you the latest cutting-edge research and commentary in bioscience.

Cell & Gene Therapy Insights

Cell & Gene Therapy Insights

Spotlight Article

Future trends in commercial cell and gene therapy: the investor’s perspective

Market & Patient Access

Gregory Bonfiglio

Gregory Bonfiglio is the Founder and Managing Partner of Proteus, LLC – an investment and advisory firm focused solely on Regenerative Medicine. Formed in 2006, Proteus provides fund management and consulting services to the regenerative medicine industry. Proteus works with cell and gene therapy companies across all stages of development from early stage entities to large public companies, as well as governmental organizations pursuing RM initiatives. Mr Bonfiglio serves on the Board of Healios KK, one of the largest publicly traded RM companies in Japan. He is on the Investment Committee of the Centre for Commercialization of Regenerative Medicine (RM Translation Center in Toronto, Canada). He is on the Advisory Board of BioBridge Global (RM Translation Center in San Antonio, Texas). He is on the ISSCR Finance Committee. Mr Bonfiglio was an early investor in the RM field, and he continues to be actively involved in the space. He has over 35 years’ experience working with technology companies. He received his BA in Mathematics (magna cum laude) from Michigan State University in 1975, and his JD (magna cum laude) from the University of Michigan Law School in 1981.

DOI: 10.18609/cgti.2019.116
Citation: Cell & Gene Therapy Insights 2019; 5(8), 1081–1089.
Open access
This content is restricted to registered users. Click here to Register or Login here.
Twitter IconVisit Our Blog